Takeda Pharmaceutical Company Limited
TAKWI
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -18.69% | -240.75% | 331.11% | -112.92% | 40.77% |
| Total Depreciation and Amortization | -19.89% | -22.51% | 0.91% | -3.12% | 1.98% |
| Total Amortization of Deferred Charges | -- | 0.42% | -- | -- | -- |
| Total Other Non-Cash Items | 151.82% | -79.77% | 38.95% | 174.32% | -65.67% |
| Change in Net Operating Assets | -380.80% | 8,234.15% | -143.85% | 131.23% | 54.65% |
| Cash from Operations | -47.13% | -68.00% | -3.75% | 35.68% | 36.51% |
| Capital Expenditure | -0.23% | 9.36% | 8.63% | 18.32% | 9.98% |
| Sale of Property, Plant, and Equipment | -84.68% | 60.95% | 85.33% | -100.00% | 76,516.98% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -68.13% | -95.52% | 148.57% | -93.38% | 974.83% |
| Other Investing Activities | -93.55% | -164.38% | -163.95% | 72.78% | 77.87% |
| Cash from Investing | -135.79% | -181.21% | -96.79% | 35.43% | 77.14% |
| Total Debt Issued | -- | 118.26% | -100.00% | -28.17% | -63.84% |
| Total Debt Repaid | 93.85% | 62.94% | 98.06% | 44.00% | -135.22% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 98.05% | 100.00% | -- | -- | -2,641.92% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 7.79% | 13.92% | -1.39% | 3.73% | -13.53% |
| Other Financing Activities | 0.56% | -11.71% | 15.42% | -27.00% | -167.35% |
| Cash from Financing | 25.11% | 75.51% | 70.97% | 89.03% | -173.30% |
| Foreign Exchange rate Adjustments | 332.90% | 110.81% | -2.93% | 132.24% | -115.26% |
| Miscellaneous Cash Flow Adjustments | -- | -195.45% | -- | -- | -- |
| Net Change in Cash | -240.82% | 47.60% | 92.80% | 518.65% | -110.91% |